Tests a new drug added to chemotherapy for advanced bowel cancer
Tests INCA33890 with chemotherapy and bevacizumab in adults with advanced colorectal cancer.
Key facts
- Who runs it
- Incyte Corporation
- Where
- Changwon-Si, Goyang-si, Seongnam, Seongnam-si, Seoul, and Suwon, South KoreaSee the 14 sitesAlso in 21 other countries, 277 sites
- Trial code
- Registry title
- A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer
- Status
- Recruiting
- Phase
- Phase 3
- People taking part
- 700 people, planned
- Started
- 5 Mar 2026
- Expected to end
- 28 Sept 2029
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- INCA33890
- Placebo
- Bevacizumab
- FOLFOX
- Record updated
- 30 October 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with stage IV colorectal cancer that has spread and cannot be removed by surgery, and who have not yet had treatment for it.
- Age
- 18 years or older
- Sex
- All sexes can join
- Disease stage
- Stage IV colorectal adenocarcinoma that cannot be removed by surgery meant to remove all of the disease. The disease must be measurable on scans (RECIST v1.1). Performance status (ECOG) of 0 or 1. Organ function must be adequate on lab tests.
- Earlier treatment
- No earlier systemic treatment for cancer that cannot be removed or has spread. Treatment given before or after surgery is allowed if the cancer did not return within 12 months of the end of that treatment.
- Biomarker or test result
- The cancer must be microsatellite stable (MSS). Tumours with MSI-H/dMMR or a BRAF V600E mutation, as shown in the medical record, are not allowed.
Main reasons for not taking part
- Brain or spinal cord (CNS) metastases that are untreated or growing
- Another cancer within the past 2 years
- Treatment with an anti-PD-(L)1 or other immune checkpoint inhibitor in the last 3 years
- Active autoimmune disease that needed systemic treatment in the past 2 years
- Earlier organ transplant, including stem cell transplant from a donor
The registry criteria, word for word
Show all 13 criteriaShow less
Who can take part
- Stage IV colorectal adenocarcinoma not amenable to curative resection
- No prior systemic treatment for unresectable or metastatic disease. Participants who received adjuvant or neoadjuvant therapy may enroll if there was no recurrence within 12 months of the end of treatment
- Measurable disease per RECIST v1.1
- ECOG performance status of 0 or 1
- Adequate organ function determined by laboratory results
Who cannot take part
- Treatment with an anti-PD-(L)1 or other immune checkpoint inhibitor for any indication within the last 3 years
- Significant concurrent and/or uncontrolled medical condition
- History of other malignancy within 2 years
- Active autoimmune disease that has required systemic treatment in the past 2 years
- History of organ transplant, including allogeneic stem cell transplantation; Other protocol-defined inclusion/exclusion criteria apply
- MSI-H/dMMR per historical data in the medical record
- BRAF V600E mutation per historical data in the medical record
- Untreated and/or progressing CNS metastases
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- How many different drug treatment plans (such as chemotherapy) have you had for cancer that has spread?
- Has a test of your tumour shown a change (mutation) in the KRAS, NRAS or BRAF genes?
- Has a test shown that your tumour is 'MSI-high' or 'dMMR'?
- Which best describes how well you can look after yourself and be active?
Where in South Korea
Also in 21 other countries, 277 sites
- Samsung Changwon HospitalChangwon-Si, South KoreaTaking people
- National Cancer CenterGoyang-si, South KoreaTaking people
- Seoul National University Bundang HospitalSeongnam, South KoreaTaking people
- CHA Bundang Medical CenterSeongnam-si, South KoreaTaking people
- Asan Medical CenterSeoul, South KoreaTaking people
- Hanyang University Seoul HospitalSeoul, South KoreaTaking people
- Kangbuk Samsung HospitalSeoul, South KoreaTaking people
- Korea University Anam HospitalSeoul, South KoreaTaking people
- Samsung Medical CenterSeoul, South KoreaNot yet recruiting
- Seoul National University HospitalSeoul, South KoreaTaking people
- Severance Hospital, Yonsei University Health SystemSeoul, South KoreaTaking people
- The Catholic University of Korea, Eunpyeong St. Mary's HospitalSeoul, South KoreaTaking people
- The Catholic University of Korea, Seoul ST. Mary's HospitalSeoul, South KoreaTaking people
- Ajou University HospitalSuwon, South KoreaTaking people
About the trial
What the trial wants to find out
The purpose of this study is to evaluate the efficacy and safety of standard-of-care chemotherapy and bevacizumab with or without INCA33890 in the first-line treatment of metastatic microsatellite stable colorectal cancer.
The 2 groups in the trial
- INCA33890Treatment being tested
INCA33890 will be administered in combination with bevacizumab and FOLFOX at the protocol-defined dose.
Treatment: INCA33890, Bevacizumab, and FOLFOX
- PlaceboPlacebo, for comparison
Placebo will be administered in combination with bevacizumab and FOLFOX at the protocol-defined dose.
Treatment: Placebo, Bevacizumab, and FOLFOX
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Official title
- A Randomized, Double-Blind, Phase 3 Study of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer
- Plain-language title
- Tests a new drug added to chemotherapy for advanced bowel cancerGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Fit questions
- Built from NCT07284849, who can take part
- Record updated
- 30 October 2026